

1 **Title:** Demonstration of antibodies against SARS-CoV-2, neutralizing or binding, in
2 seroconversion panels after mRNA-1273, BNT-162b2 and Ad26.COV2.S vaccine
3 administration

4 **Authors:** Francisco Belda^{1*}, Oscar Mora¹, Monica Lopez-Martinez², Nerea Torres², Ana
5 Vivanco², Silvia Marfil³, Edwards Pradenas³, Marta Massanella^{3,4}, Julià Blanco^{3,4,5},
6 Rebecca Christie⁶, Michael Crowley⁶

7 **Affiliations:** ¹ Research and Development, Bio Supplies Division, Grifols, 08174 Sant
8 Cugat del Vallès (Barcelona), Spain

9 ² R&D Department, Progenika Biopharma, A Grifols Company, Ibaizabal Bidea, Edificio
10 504, Parque Tecnológico de Bizkaia, 48160 Derio, Bizkaia, Spain

11 ³IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can
12 Ruti Campus, UAB, 08916, Badalona, Catalonia, Spain

13 ⁴Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, CIBERINFEC,
14 Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid, Spain

15 ⁵University of Vic–Central University of Catalonia (UVic-UCC), 08500, Vic, Catalonia,
16 Spain

17 ⁶Access Biologicals, Vista, CA 92081, USA

18 ***Corresponding Author:** Dr. Francisco Belda

19 Grifols

20 Parc Empresarial Can Sant Joan

21 Av. De la Generalitat, 152-158

22 08174 Sant Cugat del Vallès (Barcelona), Spain

23 Telephone: 34 935 710 313; Email: paco.belda@grifols.com

24 **Running Title:** Demonstration of antibodies against SARS-CoV-2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 **Abstract:**

26 Seroconversion panels were collected before and after vaccination with three COVID-19
27 vaccines: two mRNA vaccines (mRNA-1273 and BNT-162b2) and one adenovirus vector vaccine
28 (Ad26.COV2.S). The panels were tested for antibody activity by chemiluminescent
29 immunoassay, ELISA and one was tested in a pseudovirus neutralization assay.
30 Participants positive for anti-SARS-CoV-2 antibodies before vaccination (18.6%) had a higher
31 response to the first vaccine dose than participants who tested negative. For two-dose
32 vaccines, older participants showed a lower response to the first dose than younger
33 participants. All participants showed positive antibody responses after the second vaccine. For
34 the adenovirus vector vaccine, two participants did not generate antibody responses two
35 weeks and two months after vaccination. Three participants were negative at two weeks but
36 positive at two months. Pseudovirus neutralization showed good correlation with antibody
37 activity (correlation coefficient =0.78, $p < 0.0001$). Antibody responses in participants over 45
38 years old tended to be less robust.

39

40 **Keywords:**

41 SARS-CoV-2, neutralizing antibodies, binding antibodies, seroconversion panels, vaccines,
42 mRNA-1273, BNT-162b2, Ad26.COV2.S.

43 **Introduction**

44 Since the start of the SARS-CoV-2 pandemic, nearly 30 pharmaceutical
45 companies, research institutes and academic laboratories worldwide have been
46 working toward the development of effective vaccines against COVID-19. These efforts
47 have taken various approaches including mRNA, DNA, protein subunits, and
48 attenuated or non-replicating viruses. [1] Among the vaccines utilizing mRNA and
49 nanotechnology, mRNA-1273 (Moderna) and BNT-162b2 (Pfizer/BioNTech) are the
50 most advanced.

51 Within one year of the emergence of the SARS-CoV-2 virus, these two novel
52 and effective mRNA vaccines became available under emergency use authorization
53 (EUA) by the US Food and Drug Administration (FDA). The BNT162b2 vaccine contains
54 30 µg of SARS-CoV-2 full-length spike (pre-fusion conformation) mRNA administered as
55 two doses three weeks apart. The mRNA-1273 vaccine 100 µg of pre-fusion-stabilized
56 spike glycoprotein mRNA given as two doses four weeks apart. [2]

57 The BNT-162B2 vaccine (Comirnaty®, BioNTech, Mainz, Germany/Pfizer, New York,
58 NY, USA) was first utilized under an EUA beginning December 11, 2020 [3] and became
59 the first COVID-19 vaccine approved by the FDA on August 23, 2021. It was approved
60 for the prevention of COVID-19 in individuals 16 years of age and older. In addition, the
61 BNT-162B2 vaccine is available for use under an emergency use authorization (EUA) for
62 children ages 12 to 15 years and as a third booster dose in immunocompromised
63 individuals, people over 65, individuals between 16 and 64 who are at high risk of
64 severe COVID-19 and person with high environmental exposure to SARS-CoV-2 which
65 puts them at risk for severe COVID-19. [4]

66 The FDA issued an EUA for the mRNA-1273 vaccine for the prevention of
67 COVID-19 in individuals over 18 years of age on December 18, 2020. As with the EUA
68 for BNT-162b2, the EUA for mRNA-1273 was amended in August 2021 to allow the
69 administration of an additional dose to certain immunocompromised individuals. [5]

70 The Ad26.COVS vaccine (Janssen/Johnson & Johnson, Beerse, Belgium) uses a
71 recombinant, replication-incompetent human adenovirus type 26 vector. This vector
72 encodes for a full SARS-CoV-2 spike protein in a stabilized pre-fusion conformation. A
73 single dose of Ad26.COVS protected vaccinated individuals against symptomatic and
74 asymptomatic SARS-CoV-2 infection. For those who did get infected, the vaccine was
75 effective in preventing severe disease including hospitalization and death. [6]

76 Infection with SARS-CoV-2 or vaccination with an effective vaccine initiates an
77 immune response with includes the production of antibodies that bind to viral
78 proteins, i.e., binding antibodies.[7] Not all binding antibodies can block cellular
79 infiltration and/or replication by the SARS-CoV-2 virus. The subpopulation of
80 antibodies that can block these processes are called neutralizing antibodies (NAbs). It
81 is unknown when in the course of infection or after vaccination NAbs are produced or
82 if they are produced from the onset of antibody formation. While most individuals
83 produce binding antibodies in response to SARS-CoV-2 infection, not all will develop
84 NAbs to SARS-CoV-2.[8]

85 Most SARS-CoV-2 infections induce a response in the adaptive immune system.
86 [9] NAbs that prevent the virus from binding to the host-cell receptor, angiotensin
87 converting enzyme 2 (ACE2) are essential for this immune response. NAbs target the
88 receptor binding domain (RBD) of the viral spike protein and thereby inhibit ACE2

89 binding. [10, 11] These NABs may be of therapeutic value through treatments such as
90 convalescent plasma [12], and hyperimmune globulins. [13] In addition, they can serve
91 as structural templates for vaccine development. Consequently, there is a need for
92 assays that reliably and efficiently identify the most potent NABs. The gold standard to
93 detect NABs is a virus neutralization test conducted on live cells which can be
94 performed with live virus or pseudoviruses. [14] The level of neutralizing antibodies
95 that confers immunity to infection/reinfection with SARS-CoV-2 has yet to be
96 elucidated. [15]

97 Seroconversion panels are a series of blood samples collected before and after
98 the development of antibodies in response to viral infection or vaccination. These
99 panels can be useful in the development of antibody assays, determination of the
100 window period of detection (the period between infection and the appearance of
101 antibodies), and the development (validation) and manufacture (quality control) of
102 commercial antibody tests. Reliable detection of viral exposure and vaccine
103 effectiveness is a critical step in gaining control of the current COVID-19 pandemic and
104 allowing the general population to return to normal ways of life. The panels can also
105 be a source of well-defined neutralizing antibodies (before and after vaccination) that
106 can be useful in investigating their effectiveness against new SARS-CoV-2 variants. The
107 studies in this paper describe the characterization of seroconversion panels from
108 donors vaccinated for COVID-19 with the three vaccines currently available in the US:
109 BNT-162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S
110 (Janssen/Johnson & Johnson).

111 **Materials and Methods**

112 **Seroconversion Panel Collection**

113 The seroconversion panels described in this paper were derived from samples
114 collected at a hospital from volunteer donors. The donors provided informed consent
115 and their samples were collected under an approved IRB protocol ([1149706-4]
116 Diagnostic QC and Pre-Clinical Sample Collection Project: Ballad Health System
117 Institutional Review Board (IRB #00003204), Johnson City, TN, USA). These studies
118 were conducted in compliance with all applicable regulatory guidelines. The
119 seroconversion panels were comprised of serum samples collected before and after
120 administration of the COVID-19 vaccines. This study characterizes the appearance of
121 anti-SARS-CoV-2 antibodies after vaccine administration.

122 Four seroconversion panels were analyzed in this study: one mRNA-1273
123 (Moderna) n = 15 donors; two BNT-162b2 (Pfizer/BioNTech) n = 15 donors for each
124 panel; and one Ad26.COVS.2.S (Janssen/Johnson & Johnson) n= 14 donors. For mRNA-
125 based vaccines (mRNA-1273 and BNT-162b2) panels, samples were collected prior to
126 the first vaccination (objective target ≤ 2 days: sample 1), prior to the second
127 vaccination (objective target ≤ 2 days: sample 2), and after the second vaccination
128 (objective target 13-15 days; sample 3). For Ad26.COVS.2.S, samples were collected on
129 vaccination day (prior to the injection: sample 1), two weeks after vaccination (14
130 days: sample 2) and 2 months after vaccination (59-62 days: sample 3). Samples were
131 collected as plasma (in the presence of potassium EDTA) and/ or serum (in serum
132 separating tubes).

133 As previously described [16], the mRNA-1273 panel was made up of undiluted,
134 unpreserved serum samples collected from 15 participants between 22 December
135 2020 and 25 February 2021. The donors were health adults (21-76 years old) who
136 received the prescribed course of mRNA-1273 vaccines (two injections of 100 µg -
137 objective target 28 days apart). There were 10 female and 5 male donors, and all were
138 white/Caucasian.

139 The two BNT-162b2 panels were collected at different times. The first panel
140 (BNT-162b2 Panel 1) was collected between 19 February 2021 and 23 April 2021. The
141 second panel (BNT-162b2 Panel 2) was collected between 25 May 2021 and 24
142 September 2021. The BNT-162b2 panels were either undiluted, unpreserved serum or
143 EDTA-treated plasma collected from 15 donors each. These donors were healthy adults
144 36-70 years old for the first panel and 29 to 67 years old for the second panel. The
145 participants for both panels received the approved vaccination regimen (two injections
146 of BNT-162b2 30 µg – objective target 21 days apart). There were 7 female and 8 male
147 donors in panel 1 and 9 female and 6 male donors in panel 2. All the donors were
148 white/Caucasian.

149 The Ad26.COVS panel was undiluted, unpreserved serum collected from 14
150 donors between 7 March 2021 and 24 September 2021. These donors were between
151 31 and 64 years of age. There were equal numbers (n=7) of female and male donors
152 and all were white/Caucasian. These donors received the approved regimen of a single
153 injection (0.5 mL) of the Ad26.COVS vaccine.

154 All samples were stored at -20°C until analyzed. Prior to analysis, samples were
155 thawed at room temperature and mixed by inversion.

156 **CLIA and ELISA Assays**

157 The samples in the seroconversion panels were tested for the presence of anti-SARS-
158 CoV-2 antibodies using chemiluminescent immunoassays (CLIA: Liaison SARS-CoV-2 IgG assay,
159 Diasorin, Inc., Saluggia, Italy; EUA approved) and enzyme-linked immunosorbent assays (ELISA:
160 Progenika anti-SARS-CoV-2 IgG Kit, Progenika Biopharma, Derio, Bizkaia, Spain; CE-IVD certified
161 immunoassay). These assays were performed following the directions provided by the
162 manufacturers. The Diasorin assay utilizes antigens to the S1 and S2 spike protein IgG while the
163 Progenika assay utilizes only antigens to S1 IgG. The specific sequences antigens are not
164 disclosed. Since the assays were developed independently, they are assumed to be non-
165 identical.

166 A kappa correlation (JMP software 16.0) statistic test was performed to compare the
167 qualitative values between CLIA and ELISA assays.

168 **Neutralizing Antibody Determination**

169 **Cell line**

170 HEK293T cells (presumably of female origin) overexpressing wild-type human ACE-2
171 (Integral Molecular, USA) were used as target for SARS-CoV-2 spike expressing pseudovirus
172 infection. Cells were maintained in T75 flasks with Dulbecco's Modified Eagle's Medium
173 (DMEM) supplemented with 10% fetal bovine serum and 1 μ g/mL puromycin).

174 **Pseudovirus generation**

175 Pseudoviruses (HIV reporter) expressing the SARS-CoV-2 S protein and luciferase were
176 constructed using the defective HIV plasmid, pNL4-3.Luc.R-E-. The plasmid was obtained from
177 the NIH AIDS Reagent Program. [17] Expi293F cells were transfected using ExpiFectamine293
178 Reagent (Thermo Fisher Scientific, Waltham, MA, USA) with pNL4-3.Luc.R-E- and SARS-CoV-
179 2.Sct Δ 19 (Wuhan, G614 or B.1.1.7); at an 8:1 ratio, respectively. Control pseudoviruses were
180 generated by replacing the S protein expression plasmid with a vesicular stomatitis virus (VSV)-
181 G protein expression plasmid as previously reported. [18] Supernatants were harvested 48

182 hours after transfection, filtered at 0.45 μ m, frozen, and titrated on HEK293T cells
183 overexpressing wild-type human ACE-2.

184 **Neutralization assays**

185 Neutralization assays were performed in duplicate. Briefly, 200X the median tissue
186 culture infectious dose (TCID₅₀) of pseudovirus was preincubated with three-fold serial
187 dilutions (1/60–1/14,580) of heat-inactivated plasma samples in Nunc 96-well cell culture
188 plates (Thermo Fisher Scientific) for 1 h at 37°C. Then 2 x 10⁴ HEK293T/hACE2 cells treated
189 with DEAE-Dextran (Sigma-Aldrich, St. Louis, MO, USA) were added. Results were read after 48
190 h using an EnSight Multimode Plate Reader and BriteLite Plus Luciferase reagent (Perkin Elmer,
191 Waltham, MA, USA).

192 The results were normalized and the ID₅₀ (the reciprocal dilution inhibiting 50% of the
193 infection) was calculated by plotting the log of plasma dilution versus response and fitting to a
194 4-parameter equation in Prism 8.4.3 (GraphPad Software, San Diego, CA, USA). This
195 neutralization assay has been previously validated in a large subset of samples. [7]

196 **RESULTS**

197 **mRNA-1273 (Moderna) seroconversion panel**

198 As previously described [16], the pre-vaccination samples in the mRNA-1273 panel
199 showed positive values for two participants suggesting that they had been previously infected
200 with SARS-CoV-2 (participants 5 and 15). The post-vaccination samples collected from these
201 participants after the first dose showed the largest antibody responses in the panel. After the
202 first dose of mRNA-1273, samples from 13 of the 15 participants showed positive antibody
203 response by CLIA and 14 of 15 by ELISA. The two participants who tested negative after the
204 first dose of vaccine were the oldest participants in the panel (> 70 years old: participants 3
205 and 4). After the second dose, samples for all 15 of the participants were positive for anti-
206 SARS-CoV-2 antibodies (in both assays). Overall, there was good agreement between the

207 results of the CLIA and ELISA assays (Kappa coefficient = 0.947). The value of the equivocal
208 range was eliminated to perform this statistical test.

209 The post-vaccination second dose samples from the mRNA-1273 panel were tested for
210 neutralizing antibodies. The samples from all participants were positive for neutralizing
211 antibodies (Figure 1). When the neutralizing antibody results were compared with the ELISA
212 antibody detection results, a positive correlation was observed in both analyses (Correlation
213 coefficient=0.78 and p-value<0.0001).

214 **BNT-162b2 (Pfizer/BioNTech) seroconversion panels**

215 Testing (CLIA) of the pre-vaccination samples in BNT-162b2 Panel 1 gave the following
216 results (Figure 2; first point): 12 negative and 3 positive results (participants 2, 5 and 15). The
217 detection of anti-SARS-CoV-2 antibodies in these three participants indicates that they were
218 infected with the virus prior to collection of the samples.

219 Sample collected after the first vaccine injection showed 14 positive and 1 negative
220 results (Figure 2; second point). The largest antibody responses were detected in the three
221 participants (2, 5 and 15) who had detectable antibodies in their pre-vaccination samples. The
222 sample from participant 12 also showed a high antibody response to the first vaccine injection.
223 The pre-vaccination sample from this participant was close to the cutoff value for positivity.
224 The single negative sample collected after the first vaccine dose was in one of the older
225 participants (participant 1; 55-60 years old).

226 Samples collected after the second vaccine injection were positive in all 15 participants
227 (Figure 2; third point). Lower antibody responses were seen in four participants (3, 4, 7 and 14)
228 compared to the rest of the participants. These participants were between 55 and 80 years
229 old. The sample from participant 7 (60-65 years old) showed a lower level of antibody activity
230 after the second vaccine dose that that seen after the first vaccine dose.

231 Results from CLIA testing of a second BNT-162b2 seroconversion panel (BNT-162b2
232 Panel 2) showed ten negative and 5 positive anti-SARS-CoV-2 antibody responses in the pre-

233 vaccination samples (Figure 3; first point – participants 4, 8, 9, 10 and 15). As previously noted,
234 the presence of anti-SARS-CoV-2 IgG in pre-vaccination samples indicates infection with SARS-
235 CoV-2 prior to collection of the samples.

236 The samples in this panel collected after the first injection of the BNT-162b2 vaccine
237 showed 13 positive and 2 negative results (Figure 3; second point). As with Panel 1, the
238 greatest antibody responses were detected in the five participants that had detectable anti-
239 SARS-CoV-2 antibodies in their pre-vaccination samples (participants 4, 8, 9, 10 and 15). Two
240 participants had negative antibody responses after the first vaccine injection (participants 7
241 and 12). These participants were 45-50 and 25-30 years old.

242 The sample collected after the second BNT-162b2 vaccine injection were positive for
243 all 15 participants (Figure 3; third point). The lowest activity was seen in participant 12 (25-30
244 years old) 16 AU/mL just above the cutoff value of 15 AU/mL. This participant (12) was one of
245 the two participants that tested negative after the first vaccination. The other participants with
246 low antibody responses (1, 5 and 7) were 45-60 years old.

247 **Ad26.COVS (Janssen/Johnson & Johnson) seroconversion panel**

248 Testing of the pre-vaccination samples for the Ad26.COVS panel showed 13 negative
249 and 1 positive anti-SARS-CoV-2 antibody responses (Figure 4; first point). The one positive
250 sample indicates a previous SARS-CoV-2 infection in this participant (11) prior to the collection
251 of the sample.

252 The samples collected two weeks after the single-dose vaccination showed eight
253 positive and 6 negative antibody responses (Figure 4; second point). Samples from 12
254 participants showed positive responses two months after vaccination (Figure 4; third point).
255 Two participants (3 and 6) showed negative antibody responses after two weeks and two
256 months. These participants were 40-45 and 60-65 years old. The three participants that
257 showed a negative antibody response at two weeks but a positive response at two months
258 were 30-35 (n=1) and 60-65 (n=2) years old.

259 Discussion

260 Four seroconversion panels have been created by collecting serum or plasma samples
261 from participants before and after COVID-19 vaccination. Three of the panels were drawn from
262 participants who were administered one of the two-dose mRNA-based vaccines (mRNA-1273 –
263 one panel and BNT-162b2 – two panels) and one panel from participants given a single dose of
264 the replication-incompetent adenovirus-based vaccine (Ad26.COV2.S). These panels were
265 tested using CLIA and ELISA technologies. Comparison of the CLIA and ELISA results for the
266 mRNA-1273 panel showed good agreement between these assays. [16]

267 In addition, neutralization assays were conducted in this study and showed
268 congruence between the neutralization assay and the CLIA. Neutralizing activity that blocks
269 viral entry into cell has been shown to be responsible for antibody-mediated prevention of
270 coronavirus infection. [19] Neutralizing anti-SARS-CoV-2 antibodies have been shown to mainly
271 target the receptor-binding domains on the S1 region of the spike protein. [20] When
272 immunoassay results correlate with neutralization assays, as in this study, the simpler, less
273 labor-intensive immunoassays may be a useful initial indirect screen for antibody
274 neutralization activity. A similar correlation between immunoassay and neutralization results
275 has been seen in other studies. [21, 22]

276 The results from all the seroconversion panels illustrate several important points
277 regarding antibody responses to vaccination against COVID-19: 1) There is a small but
278 significant fraction (18.6%) of the general population (as measured by the participants in this
279 study) that have been infected with SARS-CoV-2 and have antibodies to the virus prior to
280 vaccination; 2) For the mRNA-based vaccines, the second dose raised anti-SARS-CoV-2
281 antibody levels in participants without a previous SARS-CoV-2 infection to the same levels as
282 those participants who had been infected with SARS-CoV-2 and had antibodies prior to
283 vaccination; 3) Antibody responses tended to be less robust in the participants over 45 years
284 old.

285 **Acknowledgements:** Michael K. James, Ph.D. is acknowledged for medical writing and
286 Jordi Bozzo, Ph.D., CMPP for editorial assistance.

287

288 **References**

- 289 1. Noor, R., *Developmental Status of the Potential Vaccines for the Mitigation of the*
290 *COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and*
291 *Moderna mRNA Vaccines*. *Curr Clin Microbiol Rep*, 2021: p. 1-8.
- 292 2. Montoya, J.G., et al., *Differences in IgG antibody responses following BNT162b2 and*
293 *mRNA-1273 vaccines*. *bioRxiv*, 2021.
- 294 3. *Emergency Use Authorization (EUA) for an unapproved product - review memorandum:*
295 *Pfizer-BioNTech COVID-19 Vaccine/BNT-162b2*. 2020 12 Oct 2021]; Available from:
296 <https://www.fda.gov/media/144416/download>.
- 297 4. *Comirnaty and Pfizer-BioNTech COVID-19 vaccine*. 2021 14 December 2021 16
298 December 2021]; Available from: [https://www.fda.gov/emergency-preparedness-and-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine)
299 [response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine)
300 [vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine).
- 301 5. *Moderna COVID-19 Vaccine*. 2021 13 December 2021 16 December 2021]; Available
302 from: [https://www.fda.gov/emergency-preparedness-and-response/coronavirus-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine)
303 [disease-2019-covid-19/moderna-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine).
- 304 6. Sadoff, J., et al., *Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-*
305 *19*. *N Engl J Med*, 2021. **384**(23): p. 2187-2201.
- 306 7. Trinite, B., et al., *SARS-CoV-2 infection elicits a rapid neutralizing antibody response*
307 *that correlates with disease severity*. *Sci Rep*, 2021. **11**(1): p. 2608.
- 308 8. Carrillo, J., et al., *Humoral immune responses and neutralizing antibodies against SARS-*
309 *CoV-2; implications in pathogenesis and protective immunity*. *Biochem Biophys Res*
310 *Commun*, 2021. **538**: p. 187-191.

- 311 9. Garritsen, A., et al., *Two-tiered SARS-CoV-2 seroconversion screening in the*
312 *Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing*
313 *antibodies*. *Infect Dis (Lond)*, 2021. **53**(7): p. 498-512.
- 314 10. Wu, Y., et al., *A noncompeting pair of human neutralizing antibodies block COVID-19*
315 *virus binding to its receptor ACE2*. *Science*, 2020. **368**(6496): p. 1274-1278.
- 316 11. Zost, S.J., et al., *Potently neutralizing and protective human antibodies against SARS-*
317 *CoV-2*. *Nature*, 2020. **584**(7821): p. 443-449.
- 318 12. Piechotta, V., et al., *Convalescent plasma or hyperimmune immunoglobulin for people*
319 *with COVID-19: a living systematic review*. *Cochrane Database Syst Rev*, 2021. **5**: p.
320 CD013600.
- 321 13. Vandeberg, P., et al., *Production of anti-SARS-CoV-2 hyperimmune globulin from*
322 *convalescent plasma*. *Tranfusion*, 2021: p. 1-5.
- 323 14. Fiedler, S., et al., *Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2*
324 *Binding in Patient Serum*. *ACS Infect Dis*, 2021. **7**(8): p. 2362-2369.
- 325 15. Bubonja-Sonje, M., et al., *Diagnostic accuracy of three SARS-CoV2 antibody detection*
326 *assays, neutralizing effect and longevity of serum antibodies*. *J Virol Methods*, 2021.
327 **293**: p. 114173.
- 328 16. Belda, F., et al., *Seroconversion panels demonstrate anti-SARS-CoV-2 antibody*
329 *development after administration of the mRNA-1273 vaccine*. *medRxiv*, 2021.
- 330 17. Connor, R.I., et al., *Vpr is required for efficient replication of human immunodeficiency*
331 *virus type-1 in mononuclear phagocytes*. *Virology*, 1995. **206**(2): p. 935-44.
- 332 18. Sanchez-Palomino, S., et al., *A cell-to-cell HIV transfer assay identifies humoral*
333 *responses with broad neutralization activity*. *Vaccine*, 2011. **29**(32): p. 5250-9.
- 334 19. Qian, Z., et al., *Identification of the Receptor-Binding Domain of the Spike Glycoprotein*
335 *of Human Betacoronavirus HKU1*. *J Virol*, 2015. **89**(17): p. 8816-27.

- 336 20. Ou, X., et al., *Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and*
337 *its immune cross-reactivity with SARS-CoV*. Nat Commun, 2020. **11**(1): p. 1620.
- 338 21. Mendrone-Junior, A., et al., *Correlation between SARS-COV-2 antibody screening by*
339 *immunoassay and neutralizing antibody testing*. Transfusion, 2021. **61**(4): p. 1181-
340 1190.
- 341 22. Tan, C.W., et al., *A SARS-CoV-2 surrogate virus neutralization test based on antibody-*
342 *mediated blockage of ACE2-spike protein-protein interaction*. Nat Biotechnol, 2020.
343 **38**(9): p. 1073-1078.

344

345

346 **Author Contributions:** All authors have participated in the conception or design of the
347 work, data collection and critical revision of the article. FB, OM, RC and NC conceived
348 the study. FB, OM and MC provided administrative support. RC and MC provided study
349 materials (developed the seroconversion panels). FB, OM, MLM, NT AV and RC
350 participated in the collection and assembly of data. SF, EP, MM and JB performed the
351 neutralization experiments. All authors participated in data analysis and interpretation,
352 manuscript writing and gave approval of the final manuscript.
353

354 **Figure Legends**

355 **Figure 1.** Antibody responses in a seroconversion panel of 15 participants after vaccination
356 with two doses of the mRNA-1273 SARS-CoV-2 vaccine (Moderna). The column in blue, shows
357 the results of neutralizing antibody titers expressed in (IC₅₀ Reciprocal Dilution). Responses ≥
358 250 were considered positive. The column in brown, shows the antibody responses obtained
359 using an enzyme-linked immunosorbent assay (ELISA). Responses ≥ 1.1 S/CO were considered
360 positive.


361 **Figure 2.** Antibody responses in a seroconversion panel of 15 subjects before and after
362 vaccination with two doses of the BNT162b2 SARS-CoV-2 vaccine (Pfizer/BioNTech) -Panel 1.
363 These results were obtained using a chemiluminescent immunoassay and are expressed as
364 arbitrary units/mL (AU/mL). Responses ≥ 15.0 units were considered positive. The first point
365 shows results from samples collected prior to the first vaccination. The second point shows the
366 results from samples collected after the first vaccination and prior to the second vaccination.
367 The third point shows the results from samples collected after the second vaccination. The
368 dashed lines correspond to the convalescent participants, while the solid lines correspond to
369 the naïve participants.

370 **Figure 3.** Antibody responses in a seroconversion panel of 15 subjects before and after
371 vaccination with two doses of the BNT162b2 SARS-CoV-2 vaccine (Pfizer/BioNTech) – Panel 2.
372 These results were obtained using a chemiluminescent immunoassay and are expressed as
373 arbitrary units/mL (AU/mL). Responses ≥ 15.0 units were considered positive. The first point
374 shows results from samples collected prior to the first vaccination. The second point shows the
375 results from samples collected after the first vaccination and prior to the second vaccination.
376 The third point shows the results from samples collected after the second vaccination. The
377 dashed lines correspond to the convalescent participants, while the solid lines correspond to the
378 naïve participants.

379 **Figure 4:** Antibody responses in a seroconversion panel of 14 subjects before vaccination with
380 one dose of the Ad26.CoV2.S SARS-CoV-2 vaccine (Janssen/Johnson & Johnson). These results
381 were obtained using a chemiluminescent immunoassay are expressed as arbitrary units/mL
382 (AU/mL). Responses ≥ 15.0 units were considered positive. The first point shows results from
383 samples collected prior the vaccination. The second point shows the results from samples
384 collected two weeks after the vaccination. The third point shows the results from samples
385 collected two months after vaccination The dashed lines correspond to the convalescent
386 participants, while the solid lines correspond to the naïve participants.
387

388


Figure 1.



389

390


391 **Figure 2.**



392

393


394 **Figure 3.**



395

396

397 **Figure 4.**



398

399